Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

Abstract Background To evaluate long-term changes in weight and metabolic parameters in people with HIV-1 (PWH) initiating first-line antiretroviral therapy. Methods Analysis of two Phase 3, randomized, double-blind, active-controlled trials (1489: NCT02607930; 1490: NCT02607956). PWH received bicte...

Full description

Saved in:
Bibliographic Details
Main Authors: Eric S. Daar, Chloe Orkin, Paul E. Sax, Debbie Hagins, Anton Pozniak, Kimberly Workowski, Cynthia Brinson, Juan Manuel Tiraboschi, Hui Liu, Chris Deaton, Cal Cohen, Sharline Madera, Jason T. Hindman, Moti Ramgopal
Format: Article
Language:English
Published: BMC 2025-04-01
Series:AIDS Research and Therapy
Subjects:
Antiretroviral therapy
Bictegravir
Body mass index
Dolutegravir
Glucose
HIV-1
Online Access:https://doi.org/10.1186/s12981-025-00732-w
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items